Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Aug 22, 2016
Dividend Increases/Decreases for the Week Ending August 19
Let's take a look at companies raising/lowering their dividends this week. Aug 18, 2016
Videos: Valuentum's Four-Part Education Workshop
Purchase the videos of Valuentum's four-part education workshop. Aug 18, 2016
Little Progress Seen in Iron Ore Market Balancing
Image Source: Peter Craven. Not much has changed in our view of the iron ore market and the players within. We continue to believe the rally in prices in early 2016 does not represent a sustainable outlook for the metal. Aug 15, 2016
Pop the Bubbly? Everyone Is Getting Rich
Image Source: Bryan Rosengrant. Federal Reserve policy and negative interest rate policy across the globe mean hurdle rates on new projects and investments are approaching zero. As “acceptable” returns fall, asset prices are being bid up to nosebleed levels. Everyone is getting rich, but what will the fallout be? Aug 15, 2016
Priceline Higher After Outperforming Conservative Guidance
Best Ideas Newsletter portfolio holding Priceline reported a solid second quarter of 2016 as the summer travel season began. Aug 15, 2016
Brand Image Taking Center Stage in Aspirational Goods
Coach, Michael Kors, and other "aspirational" goods sellers have been forced to adjust their strategies in an increasingly difficult operating environment. Aug 14, 2016
Dividend Increases/Decreases for the Week Ending August 12
Let's take a look at companies raising/lowering their dividends this week. Aug 12, 2016
Industrials Empty Tool Box Amid Tough Operating Environment
Let’s take a look at calendar second-quarter reports for a variety of industrial entities. Aug 11, 2016
Nelson’s Valuentum(ology) on Buffett
Best Ideas Newsletter portfolio holding Berkshire Hathaway is bumping against all-time highs, and frankly, we can’t be more pleased. Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492493494495496497498499500 501502503504505506507508509510511512513514515516517518519520 521522523524525526527528529530531532533534535536537538539540 541542543544545546547548549550551552553554555556557558559560 561562563564565566567568569570next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|